Intellipharmaceutics International Inc. (IPCIF)
| Market Cap | 6.22M |
| Revenue (ttm) | 1.40M |
| Net Income (ttm) | -3.39M |
| Shares Out | 33.09M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 15 |
| Last Price | $0.2197 |
| Previous Close | $0.2100 |
| Change ($) | 0.0097 |
| Change (%) | 4.62% |
| Day's Open | 0.2000 |
| Day's Range | 0.2000 - 0.2197 |
| Day's Volume | 3,226 |
| 52-Week Range | 0.0588 - 0.4800 |
TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...
TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resear...
TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...
TORONTO, ON / ACCESSWIRE / December 23, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...
About IPCIF
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for... [Read more...]
| Industry Biotechnology | Founded 1998 |
| CEO Isa Odidi | Employees 13 |
| Stock Exchange OTCMKTS | Ticker Symbol IPCIF |
Financial Performance
In 2020, IPCIF's revenue was $1.40 million, a decrease of -59.73% compared to the previous year's $3.48 million. Losses were -$3.39 million, -58.06% less than in 2019.